ClinConnect ClinConnect Logo
Search / Trial NCT05444517

Interscalene Block Versus Combined Infraclavicular-Anterior Suprascapular Blocks for Shoulder Surgery

Launched by UNIVERSITY OF CHILE · Jul 1, 2022

Trial Information

Current as of June 26, 2025

Recruiting

Keywords

Postoperative Shoulder Analgesia Diaphragmatic Paralysis Alternative Blocks

ClinConnect Summary

This clinical trial is investigating two different types of nerve blocks used for pain relief after shoulder surgery. The standard method, called the interscalene block (ISB), can sometimes cause breathing issues due to diaphragm paralysis. This trial aims to see if a new combination of nerve blocks, known as the combined infraclavicular-anterior suprascapular nerve blocks (ICB-ASSNB), can provide similar pain relief without the risk of breathing problems. Researchers are hoping that the new method will be just as effective for managing pain after surgery.

The trial is currently looking for participants who are undergoing arthroscopic shoulder surgery and are generally healthy (classified as American Society of Anesthesiologists classes 1-3) with a body mass index between 20 and 35. Those who are pregnant, have certain health conditions, or have specific allergies will not be eligible to participate. If you join the trial, you can expect to receive one of the two nerve blocks and will be monitored for pain relief and any side effects. This study is important because finding a safer method for pain management can greatly improve recovery experiences for patients with shoulder surgery.

Gender

ALL

Eligibility criteria

  • Inclusion Criteria:
  • Patients undergoing arthroscopic shoulder surgery
  • American Society of Anesthesiologists classification 1-3
  • Body mass index between 20 and 35 kg/mt2
  • Exclusion Criteria:
  • Adults who are unable to give their own consent
  • Pre-existing neuropathy (assessed by history and physical examination)
  • Coagulopathy (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. platelets ≤ 100, International Normalized Ratio ≥ 1.4 or prothrombin time ≥ 50)
  • Obstructive or restrictive pulmonary disease (assessed by history and physical examination)
  • Renal failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. creatinine ≥ 100)
  • Hepatic failure (assessed by history and physical examination and, if deemed clinically necessary, by blood work up i.e. transaminases ≥ 100)
  • Allergy to local anesthetics (LAs)
  • Pregnancy
  • Prior surgery in the neck or infraclavicular region
  • Chronic pain syndromes requiring opioid intake at home

About University Of Chile

The University of Chile, a leading academic institution in South America, is dedicated to advancing medical research and improving public health through innovative clinical trials. With a strong emphasis on collaboration among multidisciplinary teams, the university leverages its extensive resources and expertise to conduct rigorous and ethically sound studies. By integrating cutting-edge scientific methodologies and fostering partnerships with healthcare providers, the University of Chile aims to contribute valuable insights to the medical community and enhance patient care both locally and globally.

Locations

Santiago, Metropolitana, Chile

Patients applied

0 patients applied

Trial Officials

Julián Aliste, MD

Principal Investigator

University of Chile

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Similar Trials